Companies / EVAX
Evaxion A/S (EVAX)
Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid leukemia. Its programs also include vaccines that are in pre-clinical stage, which includes EVX-B1, a multi-component prophylactic vaccine targeting skin and soft tissue infections with S. aureus bacteria; EVX-B2 to target multi-component prophylactic vaccine against gonorrhea bacteria; EVX-B3 to target bacterial pathogen associated with repeated infections; and EVX-V1, a multi-component prophylactic vaccine candidate for cytomegalovirus. The company was formerly known as Evaxion Biotech A/S and changed its name to Evaxion A/S in May 2025. Evaxion A/S was incorporated in 2008 and is based in Horsholm, Denmark.
Ticker EVAX Exchange Nasdaq Sector Healthcare Industry Biotechnology Market cap $23.19M 52-week range $2.42 - $6.92
Valuation Share price $2.54 (close of Nov 18, 2026) P/E (TTM) -2.78x Price to book 1.36x Price to free cash flow -3.49x Enterprise value $7.46M Book value per share $2.04
Price performance Period Change 1 day -8.63% 5 days -12.71% 1 month -10.25% 3 months -19.37% 6 months -37.90% Year to date -46.75% 1 year -51.71% 3 years -93.04% 5 years -99.07% All time -99.49%
Short interest As of Oct 30, 2026 Short % of float 0.36% Shares short 27.57K Days to cover 0.15 Change since prior report -58.88% Source FINRA consolidated short interest
Profitability and growth Return on equity -45.23% Return on invested capital -33.92% Return on assets -27.13% Return on capital employed -38.23% Net margin -102.38% EBITDA margin -122.66% Revenue growth 125.12%
Cash flow and balance sheet Free cash flow yield (TTM) -28.62% Current ratio 5.85x Net debt to EBITDA 2.21x
Latest reported year Period end Dec 31, 2025 Fiscal year 2025 Revenue $7.53M EBITDA -$9.23M Net income -$7.71M Earnings per share $-1.00 Research and development $9.97M Interest expense $4.00M Shares outstanding 6.41M
Income statement by year Period end Revenue Net income EPS 2025-12-31 $7.53M -$7.71M -$1.00 2024-12-31 $3.34M -$10.57M -$10.00 2023-12-31 $73.00K -$22.13M -$40.50 2022-12-31 - -$23.17M -$49.00 2021-12-31 - -$24.53M -$63.00 2020-12-31 - -$15.02M -$48.50 2019-12-31 - -$11.20M -$40.50 2018-12-31 - -$5.54M -$21.43
Margins and returns by year Period end Net margin Return on equity Return on capital 2025-12-31 -102.38% -45.23% -33.92% 2024-12-31 -316.00% - -165.04% 2023-12-31 -30,308.22% - - 2022-12-31 - -279.04% -131.98% 2021-12-31 - -75.63% -71.02% 2020-12-31 - -213.38% -212.68% 2019-12-31 - -119.58% -106.81% 2018-12-31 - - -63.23%
Cash and debt by year Period end Cash Debt 2025-12-31 $23.23M $5.35M 2024-12-31 $5.95M $8.01M 2023-12-31 $5.58M $8.49M 2022-12-31 $13.18M $7.86M 2021-12-31 $32.17M $1.04M 2020-12-31 $5.83M - 2019-12-31 $9.56M - 2018-12-31 $7.43M - 2017-12-31 $468.00K -
Free cash flow by year Period end Free cash flow Stock-based compensation 2025-12-31 -$6.64M $307.00K 2024-12-31 -$12.94M $357.00K 2023-12-31 -$17.78M $479.00K 2022-12-31 -$26.07M $942.00K 2021-12-31 -$23.23M $1.38M 2020-12-31 -$12.59M $3.41M 2019-12-31 -$7.08M $2.36M 2018-12-31 -$2.00M $2.07M
Investor relations Next earnings report Next confirmed report Nov 19, 2026 Past earnings dates Reported Fiscal period EPS estimate 2026-08-20 Jun 2026 - 2026-05-07 Mar 2026 - 2026-03-05 Dec 2025 - 2025-11-06 Sep 2025 - 2025-08-14 Jun 2025 -$0.50 2025-05-27 Mar 2025 -$0.65 2025-04-01 Dec 2024 - 2024-10-31 Sep 2024 -$0.12
Filings and sources Company website evaxion.ai SEC filings 10-K, 10-Q and 8-K on EDGAR Earnings calendar All upcoming reports
Similar companies Vertex Pharmaceuticals Inc (VRTX) · Regeneron Pharmaceuticals, Inc. (REGN) · Moderna, Inc. (MRNA) · Incyte Corp (INCY) · Insmed Inc (INSM) · Bio-Techne Corp (TECH) · Thermo Fisher Scientific Inc. (TMO) · Danaher Corp (DHR)
All Healthcare companies
Understanding these figures
Price-to-earnings ratio · Short interest · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades